Moderna, Inc. (MRNA) Stock Price & Analysis
Moderna, Inc. (MRNA) fell 3.59% to USD 140.33 as of September 9, 2026 at 09:06 UTC, according to Nexqual real-time market data.
MRNA last closed at USD 145.55; the session ranged USD 139.7–147.5 on volume of 10,254,321 shares. Market capitalization is $56.02B, with a 52-week range of USD 22.28–176.66 (NMS). Source: Nexqual, September 9, 2026 at 09:06 UTC.
Key Statistics (as of September 9, 2026 at 09:06 UTC)
| Price | USD 140.33 |
|---|---|
| Change | ▼ 3.59% (down) |
| Previous Close | USD 145.55 |
| Open | USD 145.72 |
| Day Range | USD 139.7 – 147.5 |
| 52-Week Range | USD 22.28 – 176.66 |
| Volume | 10,254,321 shares |
| Market Cap | $56.02B |
| Exchange | NMS |
Technical Analysis (MRNA)
Nexqual's technical model rates MRNA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 09:06 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.7 (neutral) |
| vs SMA50 | Above (USD 86.96) |
| MACD | 20.57 (positive) |
Analyst Ratings (MRNA)
Wall Street analysts rate MRNA "Hold" based on 18 analysts, with a mean price target of USD 116.5 (range USD 45–170), per Nexqual as of September 9, 2026 at 09:06 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 116.5 |
| High Target | USD 170 |
| Low Target | USD 45 |
| Buy / Hold / Sell | 5 / 16 / 2 |
Earnings (MRNA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -1.31 |
| Revenue Estimate | $894.97M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.97 vs est -2.06 ▲ beat |
| 2026-03-31 | USD -3.4 vs est -3.88 ▲ beat |
| 2025-12-31 | USD -2.11 vs est -2.6 ▲ beat |
| 2025-09-30 | USD -0.51 vs est -2.18 ▲ beat |
Source: Nexqual, September 9, 2026 at 09:06 UTC.
Financials & Fundamentals (MRNA)
| Total Revenue | $2.23B |
|---|---|
| Revenue Growth (YoY) | +2.10% |
| Gross Margin | -66.02% |
| Operating Margin | -557.93% |
| Profit Margin | -141.43% |
| ROE | -39.00% |
| Debt / Equity | 19.04 |
| Current Ratio | 2.3 |
| Total Cash | $5.14B |
| Total Debt | $1.29B |
| Free Cash Flow | $299.25M |
Source: Nexqual, September 9, 2026 at 09:06 UTC.
Financial Health Score (MRNA)
Nexqual rates Moderna, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 09:06 UTC.
| Growth | Critical — Revenue -40% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $5.14B cash vs $1.29B debt, net cash position |
| Cash Flow | Strong — FCF $299M, 15% margin |
| Efficiency | Critical — ROE -39%, ROA -13.3% |
Ownership (MRNA)
| Insider Ownership | +7.32% |
|---|---|
| Institutional Ownership | +80.57% |
| Shares Outstanding | 399.24M |
| Float | 372.26M |
| Short % of Float | +16.16% |
Source: Nexqual, September 9, 2026 at 09:06 UTC.
Leadership (MRNA)
Moderna, Inc. is led by Stéphane Bancel (age 52), CEO & Director, per Nexqual as of September 9, 2026 at 09:06 UTC.
| CEO & Director | Stéphane Bancel (age 52) |
|---|---|
| President | Stephen Hoge (age 49) |
| Chief Financial Officer | James M. Mock (age 48) |
| Senior Vice President of Commercial Vaccines | Patrick Norman Bergstedt (age 63) |
Major Backers & Investors (MRNA)
Notable institutional backers of Moderna, Inc. include FMR, LLC, Capital Group, Baillie Gifford, according to Nexqual as of September 9, 2026 at 09:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 12.99% |
| Capital Group | 5.58% |
| Baillie Gifford | 4.56% |
| Growth Fund of America | 3.75% |
| Fidelity | 3.03% |
| Morgan Stanley | 2.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.34% |
| BlackRock | 8.88% |
| State Street | 3.94% |
| Geode Capital | 2.43% |
Source: Nexqual, September 9, 2026 at 09:06 UTC.
From Moderna, Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Any mRNA and LNP components that do not escape the endosome are typically delivered to lysosomes where they are degraded by the natural process of cellular digestion. 9 Table of Contents Examples of tools we developed by using our platform include proprietary LNP formulations that address the steps of mRNA delivery, including cell uptake, endosomal escape, and subsequent lipid metabolism, and for avoidance of counterproductive interactions with the immune system.
- We pursue updated vaccine compositions based on guidance from the FDA, and other regulatory bodies including European Medicines Agency (EMA) and the World Health Organization (WHO), with the goal of broadening vaccine-induced immunity and providing protection against circulating SARS-CoV-2 variants.
- We have developed an RSV vaccine (mRNA-1345 or mRESVIA) for adults. mRESVIA encodes an engineered form of the RSV F protein stabilized in the prefusion conformation and is formulated in our proprietary LNP.
- We filed for FDA approval for mRNA-1083 in November 2024 and also submitted regulatory applications in other geographies, including the EU, Canada, Australia and the UK.
Partnerships
- In September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement).
- In January 2026, we entered into a strategic collaboration with Recordati, an international pharmaceutical group, to advance mRNA-3927 through the final stages of clinical development and, if approved, global commercialization.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVAX | Novavax, Inc. | USD 10.19 | ▼ 1.45% |
| BNTX | BioNTech SE | USD 98.66 | ▼ 4.1% |
| ZM | Zoom Communications, Inc. | USD 96.44 | ▼ 1.73% |
| NIO | NIO Inc. | USD 3.79 | ▼ 1.81% |
| PFE | Pfizer, Inc. | USD 27.79 | ▼ 3.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 09:06 UTC. This page is informational and not investment advice.